Amendment of Statement of Principles concerning fibrosing interstitial lung disease No. 67 of 2012

Administered by Department of Veterans' Affairs

Legislation au F2012L01812 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 67 OF 2012

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority) has determined, under subsection 196B(3) & (8) of the Veterans’ Entitlements Act 1986 (the VEA) Statement of Principles Instrument No. 67 of 2012.

 

2.             This Instrument amends Statement of Principles Instrument No. 36 of 2009, as amended by Instrument No. 60 of 2010 and Instrument No. 80 of 2011, concerning fibrosing interstitial lung disease, by:

 

  • Inserting new factors 6(sa) & 6(lla) concerning 'smoking'; and
  • Inserting new factor 6(llb) concerning 'gastro-oesophageal reflux disease' for clinical worsening of fibrosing interstitial lung disease.

 

3.             This Instrument also specifies a date of effect for the amendment in accordance with subsection 12(1)(a) of the Legislative Instruments Act 2003.

 

4.             Prior to determining this Instrument, the Authority advertised its intention to undertake two focussed investigations in relation to fibrosing interstitial lung disease in the Government Notices Gazettes of 18 May 2011 and 2 November 2011, and circulated a copy of the notices of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants. The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  Three submissions were received for consideration by the Authority during the investigation.

 

5.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny Act 2011). A Statement of Compatibility with Human Rights follows.

 

6.             The determining of this Instrument finalises the investigations in relation to fibrosing interstitial lung disease as advertised in the Government Notices Gazettes of 18 May 2011 and 2 November 2011.

 

7.             A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

 

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

 


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 67 of 2012

Kind of Injury, Disease or Death: Fibrosing interstitial lung disease

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have fibrosing interstitial lung disease;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • includes new factors which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, fibrosing interstitial lung disease is connected with the circumstances of eligible service rendered by a person;
  • amends Instrument No. 36 of 2009, as amended by Instrument No. 60 of 2010 and Instrument No. 80 of 2011; and
  • reflects developments in the available sound medical-scientific evidence concerning fibrosing interstitial lung disease which have occurred since those earlier instruments were determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 67 of 2012 amends the Statement of Principles concerning fibrosing interstitial lung disease, as part of the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative instrument addresses the gap in the recognition of contributing factors to fibrosing interstitial lung disease, specifically smoking and gastro-oesophageal reflux disease, in the context of service-related claims by veterans and serving members of the Defence Force. The Instrument was determined by the Repatriation Medical Authority under the authority vested in it by the Veterans’ Entitlements Act 1986 and is intended to enhance the medico-scientific quality of outcomes under the respective Acts. The policy objective is to ensure that the qualifying conditions for benefits are reasonable, proportionate, and transparent, while also promoting the human rights of veterans and their dependants, including the right to social security and the right to an adequate standard of living. This Instrument is compatible with human rights as it does not derogate from them and promotes various human rights by facilitating the assessment and determination of social security benefits and compensation.

Scope and Application

The Repatriation Medical Authority Instrument No. 67 of 2012 applies to veterans and service personnel who are eligible for benefits under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). The Act amends the Statement of Principles concerning fibrosing interstitial lung disease by introducing new factors related to smoking and gastro-oesophageal reflux disease, which are to be considered in assessing the connection between the disease and service rendered. The legislative instrument is designed to facilitate the process for claimants and the Repatriation Commission by clarifying the circumstances under which medical treatment and compensation can be provided. This includes aiding the review of decisions by the Veterans' Review Board and the Administrative Appeals Tribunal. The changes reflect advancements in medical-scientific evidence since the previous amendments. The instrument is technically focused and aims to enhance the quality of medico-scientific outcomes under the VEA and the MRCA. There are no exclusions or exemptions specified in the document, and the instrument is compatible with human rights as it promotes the rights of veterans, service personnel, and their dependents, including their right to social security, an adequate standard of living, and health.

Key Provisions

The Repatriation Medical Authority Instrument No. 67 of 2012 amends Statement of Principles Instrument No. 36 of 2009, as subsequently modified by Instruments No. 60 of 2010 and No. 80 of 2011, by introducing new factors related to fibrosing interstitial lung disease (section 2). Specifically, the Instrument introduces new factors 6(sa) and 6(lla) concerning smoking and new factor 6(llb) concerning gastro-oesophageal reflux disease for clinical worsening of the condition (section 2). This legislative change is effective as of the date specified in subsection 12(1)(a) of the Legislative Instruments Act 2003 (section 3). The Authority determined this Instrument following investigations announced in the Government Notices Gazettes of 18 May 2011 and 2 November 2011, during which submissions were invited from relevant parties, including the Repatriation Commission, veterans’ organisations, and experts in the field (section 4). The Repatriation Medical Authority Instrument No. 67 of 2012 imposes specific obligations on parties and entities governed by the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). These obligations include facilitating the process of making claims and assessing eligibility for medical treatment and compensation related to fibrosing interstitial lung disease. The Instrument requires that the new factors introduced must be considered when determining the connection between the disease and service rendered (section 2). Additionally, the Authority must ensure that the new factors are grounded in the most recent sound medical-scientific evidence, reflecting advancements since the previous amendments. Under the Repatriation Medical Authority Instrument No. 67 of 2012, there are no specific offences or penalties outlined for breaches of the Instrument itself. However, any breaches of the provisions of the VEA and MRCA, in which this Instrument operates, may incur civil or criminal penalties as stipulated in those respective Acts. For instance, false claims or fraudulent activities under the VEA can lead to penalties such as fines or imprisonment, with the exact penalties varying according to the severity and nature of the offence. The Legislative Instrument ensures compliance with human rights by promoting the rights of veterans and other eligible persons, such as their dependents, without infringing upon their rights (section 4). The compatibility of the Repatriation Medical Authority Instrument No. 67 of 2012 with human rights is affirmed, as it does not derogate from any human rights and actively promotes several, including the right to social security, an adequate standard of living, and the highest attainable standard of physical and mental health (section 4). The Instrument supports the assessment and determination of benefits, thereby facilitating the enjoyment of these rights by eligible individuals. The Authority has ensured that the new factors introduced are consistent with international human rights instruments, promoting the rights of veterans, current and former Defence Force members, and their dependents.

Legal classification tags

Area of Law
Veterans' Affairs
Instrument
Statutory Instrument
Concepts
Definitions & Interpretation
Offence Provisions
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.